Dried Amnion Tissue Inhalation for Insulin Lung Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inhalable insulin therapies, such as Afrezza, can cause lung function decline and are contraindicated in patients with chronic lung diseases, while exercise-induced pulmonary hemorrhage is a condition affecting athletes, necessitating effective treatments for lung disorders.
Innovation Solution
Compositions including dried amnion tissue preparations and/or dried stem cell preparations, formulated for inhalation, are used to treat and prevent lung disorders induced by inhalable insulin therapy and exercise-induced pulmonary hemorrhage, combining with therapeutic agents, growth factors, and lung surfactants like DPPC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If inhalable insulin therapy is administered to achieve glycemic control, then blood glucose levels are improved, but lung function declines over time
Solution Approach 1:
The patent introduces a counteracting composition containing anti-inflammatory agents, antioxidants, or bronchodilators as an intermediary treatment. This composition is co-administered or sequentially administered with inhalable insulin to neutralize the harmful oxidative stress and inflammation caused by insulin particles in the lungs, thereby protecting lung function while maintaining glycemic control
Solution Approach 2:
The patent applies preliminary anti-action by administering protective compositions containing anti-inflammatory agents or antioxidants before or concurrently with inhalable insulin therapy. This preemptive approach prevents the development of lung function decline by counteracting the oxidative stress and inflammation that would otherwise be caused by insulin accumulation in the lungs
2Quantity of substance
If inhalable insulin therapy is used for glycemic control, then diabetes management is improved, but adverse reactions such as cough and throat irritation occur
Solution Approach 1:
The patent introduces a protective composition containing mucosal protective agents, anti-inflammatory agents, or antioxidants as an intermediary treatment. This composition is administered to the respiratory tract to protect the mucosa from irritation caused by inhalable insulin particles, thereby reducing adverse reactions like cough and throat pain while maintaining the glycemic control benefits
Solution Approach 2:
The patent converts the harmful effect of insulin particles causing mucosal irritation into a beneficial outcome by co-administering compositions that enhance mucosal protection and reduce inflammation. The same insulin particles that cause irritation are paired with protective agents that transform the adverse mucosal interaction into a tolerated or even beneficial therapeutic effect
3Quantity of substance
If inhalable insulin is administered to patients with chronic lung disease, then glycemic control is achieved, but the treatment is contraindicated due to lung function decline
Solution Approach 1:
The patent introduces a protective composition containing anti-inflammatory agents, antioxidants, or bronchodilators as an intermediary treatment that enables patients with chronic lung disease to safely receive inhalable insulin. This composition is co-administered to counteract the lung function decline that would otherwise occur, thereby expanding treatment eligibility to include patients with asthma, COPD, or other chronic lung conditions
Solution Approach 2:
The patent applies preliminary action by administering protective compositions to patients with chronic lung disease before or concurrently with inhalable insulin therapy. This preliminary protection prepares the respiratory system to tolerate insulin administration, thereby enabling treatment in patient populations that would traditionally be contraindicated
Data Source
AI summary
This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.